Medical cannabis for intractable epilepsy in childhood: A review

Bruria Ben-Zeev*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


In recent years, cannabis has been gaining increasing interest in both the medical research and clinical fields, with regard to its therapeutic effects in various disorders. One of the major fields of interest is its role as an anticonvulsant for refractory epilepsy, especially in the pediatric population. This paper presents and discusses the current accumulated knowledge regarding artisanal cannabis and Epidiolex®, a United States Food and Drug Administration (FDA)-approved pure cannabidiol (CBD), in epilepsy management in pediatrics, by reviewing the literature and raising debate regarding further research directions.

Original languageEnglish
Article numbere0004
JournalRambam Maimonides Medical Journal
Issue number1
StatePublished - Jan 2020


  • Artisanal cannabis
  • CBD
  • Dravet syndrome
  • Intractable epilepsy
  • Lennox-Gastaut syndrome


Dive into the research topics of 'Medical cannabis for intractable epilepsy in childhood: A review'. Together they form a unique fingerprint.

Cite this